REN and myocardial infarction: M.A.P.: member of the RED‐HF Clinical Endpoint Committee and Executive Committee (no payments in the last 12 months); grants from Novartis and Sanofi; consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, DalCor, Gilead, GalaxoSmithKline, Janssen, Lilly USA, The Medicines Company, Merck, Novartis, Novo Nordisk, Relypsa, Sanofi, Thrasos, Genzyme and Teva; The Brigham and Women's Hospital has patents for the use of inhibitors of the renin–angiotensin system in selected survivors of myocardial infarction with Novartis.